A Study of CA-170 in participants with Advanced Tumours and Lymphomas
Research type
Research Study
Full title
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas
IRAS ID
214065
Contact name
Simon Pacey
Contact email
Sponsor organisation
Curis, Inc.
Eudract number
2016-002203-26
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 8 months, 28 days
Research summary
The study drug, CA-170, is an experimental medicine which means it has not been approved by the drug approval agency. This is the first study in which the study drug is being given to humans. Potential participants will be invited to take part who have advanced solid tumours or lymphomas who cannot tolerate, are not expected to benefit from, or are otherwise ineligible for other standard treatment for their condition (including approved drugs immune checkpoint inhibitors, when applicable). This study is designed to determine the safety and tolerability of the study drug, including the maximum tolerated dose in patients with solid tumours or lymphomas. In addition the study includes attempts to better understand of the effects of CA170 in tumours. This study will have several treatment cycles, each lasting 21 days. Participants can continue to receive study drug for as long as they are deriving clinical benefit, until either disease progression or intolerable toxicity occurs. About 300 participants will be in the study across Europe.
REC name
London - Chelsea Research Ethics Committee
REC reference
17/LO/0145
Date of REC Opinion
13 Apr 2017
REC opinion
Further Information Favourable Opinion